{"commentary":{"count":49,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":23,"podcast":14,"youtube":12},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03143153\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CheckMate 648","nct_id":"NCT03143153","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-648-nct03143153. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CheckMate 648","arms":[{"description":null,"label":"Nivolumab + Ipilimumab","type":"EXPERIMENTAL"},{"description":null,"label":"Nivolumab + Cisplatin + Fluorouacil","type":"EXPERIMENTAL"},{"description":null,"label":"Cisplatin + Fluorouracil","type":"ACTIVE_COMPARATOR"}],"collaborators":["Ono Pharmaceutical Co., Ltd."],"completion_date":{"date":"2025-01-13","type":"ACTUAL"},"conditions":["Various Advanced Cancer"],"enrollment":{"count":970,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","type":"BIOLOGICAL"},{"name":"Ipilimumab","type":"BIOLOGICAL"},{"name":"Cisplatin","type":"DRUG"},{"name":"Fluorouracil","type":"DRUG"}],"last_update":"2026-02-17","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2021-01-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS) in Participants With Tumor Cell PD-L1","timeFrame":"From the date of randomization to up to the date of death (up to approximately 20 months)"},{"measure":"Progression-free Survival (PFS) as Assessed by BICR in Participants With Tumor Cell PD-L1","timeFrame":"From the date of randomization to up to the date of the first documented disease progression or death (up to approximately 9 months)"}],"references":[{"citation":"Zhang Y, Li C, Du K, Pengkhun N, Huang Z, Gong M, Li Y, Liu X, Li L, Wang D, Wang C, Chen F, Li J. Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis. Immunotherapy. 2023 Jul;15(10):737-750. doi: 10.2217/imt-2022-0236. Epub 2023 May 4.","pmid":"37139963","type":"DERIVED"},{"citation":"Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50). Esophagus. 2023 Apr;20(2):291-301. doi: 10.1007/s10388-022-00970-1. Epub 2022 Nov 19.","pmid":"36401133","type":"DERIVED"},{"citation":"Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380.","pmid":"35108470","type":"DERIVED"}],"start_date":{"date":"2017-06-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin","url":"https://clinicaltrials.gov/study/NCT03143153"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-648-nct03143153"}